|
시장보고서
상품코드
2091884
폐렴구균 백신 시장 규모, 점유율 및 성장 분석 : 백신 유형별, 적응증별, 연령층별, 부문별, 유통 채널별, 지역별 - 업계 예측(2026-2033년)Pneumococcal Vaccines Market Size, Share, and Growth Analysis, By Vaccine Type, By Indication, By Age Group, By Sector, By Distribution Channel, By Region - Industry Forecast 2026-2033 |
||||||
세계의 폐렴구균 백신 시장 규모는 2024년에 86억 6,000만 달러로 평가되며, 2025년 92억 달러에서 2033년까지 148억 8,000만 달러로 확대할 전망이며, 예측 기간(2026-2033년)에 CAGR 6.2%로 성장할 것으로 전망되고 있습니다.
세계 폐렴구균 백신 시장은 폐렴, 수막염, 패혈증 등 중증 질환을 유발하는 병원체인 폐렴구균(Streptococcus pneumoniae)에 의한 감염증과 싸우기 위한 결합형 및 다당류 백신의 수요 증가에 힘입어 인상적인 성장을 달성하고 있습니다. 이 시장은 특히 전 세계 소아 예방접종 프로그램의 도입과 저·중소득 국가에서의 백신 접종 구상에 대한 자금 지원을 위한 각국 정부의 노력의 영향을 받고 있으며, 이는 합리적인 가격의 백신에 대한 수요를 촉진하고 있습니다. 각국의 보건부가 정기 예방접종에 자금을 배정하는 가운데, 제조업체와 지역 기업 간의 제휴가 확대되고 있으며, 이를 통해 생산 능력 향상과 경쟁력 있는 가격 책정이 실현되고 있습니다. 또한 Gavi가 지원하는 백신 프로그램의 전개와 같은 성공 사례는 전략적인 자금 지원이 시장 활동을 어떻게 활성화하고, 전 세계에서 첨단 백신의 개발 및 유통 기회를 확대하며, 건강 성과 향상으로 이어지는지를 보여주고 있습니다.
세계 폐렴구균 백신 시장의 성장 요인
전 세계 각국 정부가 영유아, 고령자 및 고위험군을 대상으로 폐렴구균 백신을 국가 예방접종 프로그램에 포함시키고 있는 만큼, 전 세계 폐렴구균 백신 시장은 인상적인 성장을 달성하고 있습니다. 이러한 정책 전환으로 인해 공공 부문과 민간 부문 모두에서 지속적인 수요가 발생하고 있으며, 제조업체들은 생산 능력 강화와 견고한 유통 시스템 구축을 위한 투자를 추진하고 있습니다. 보건 당국이 폐렴구균 백신을 정기적인 보건 서비스에 포함시킴으로써, 더 광범위한 인구층에 대한 예방접종률을 높이고, 의료 종사자 및 간병인들의 신뢰를 높이고 있습니다. 이러한 안정적인 구매 패턴은 수입원을 안정화시킬 뿐만 아니라, 백신 개선을 위한 지속적인 연구개발을 촉진하고 시장의 추가적인 확장을 지원하고 있습니다.
세계 폐렴구균 백신 시장의 제약 요인
폐렴구균 백신에 따른 높은 비용은, 특히 저·중소득 지역에서 의료제도에 있으며, 중대한 재정적 과제가 되고 있습니다. 조달 비용이 공중보건 예산을 초과할 경우, 보건 당국은 대체 조치를 선택하거나 백신 도입을 완전히 연기할 가능성이 있습니다. 이러한 경제적 제약으로 인해 접종 가능한 백신 회수가 줄어들고, 질병 유병률이 가장 높은 지역의 시장 접근성이 제한됩니다. 그 결과, 제조사 입장에서는 수요가 불안정해져 규모의 경제를 달성하는 능력이 저해될 것이며, 가까운 시일 내에 각 대륙에서 새로운 백신 제제의 전 세계적 보급이 지연될 가능성이 있습니다.
세계 폐렴구균 백신 시장의 동향
전 세계 폐렴구균 백신 시장에서는 의료제도 내에서 고령자 및 고위험 성인 집단을 보호하는 것의 중요성이 점점 더 인식됨에 따라 성인을 대상으로 한 예방접종을 도입하는 뚜렷한 추세가 나타나고 있습니다. 이러한 변화는 세균성 폐렴이 초래하는 막대한 부담에 대한 인식이 높아진 것과 고령화를 반영한 인구 동태의 변화에 힘입어 가속화되고 있습니다. 각국의 예방접종 프로그램이 지침을 확대하여 성인 접종 대상까지 포함함에 따라 접합백신과 다당류 백신 모두에 대한 수요가 급증하고 있습니다. 그 결과, 각 제조사들은 전 세계 다양한 분야의 노인 요양 시설 및 만성질환 진료소를 대상으로 한 유통 채널 강화를 목표로, 제품 개발과 전략적 마케팅에 주력하고 있습니다.
자주 묻는 질문
목차
서론
조사 방법
개요
시장 역학과 전망
주요 시장 인사이트
세계의 폐렴구균 백신 시장 규모 : 백신 유형별
세계의 폐렴구균 백신 시장 규모 : 적응증별
세계의 폐렴구균 백신 시장 규모 : 연령층별
세계의 폐렴구균 백신 시장 규모 : 부문별
세계의 폐렴구균 백신 시장 규모 : 유통 채널별
세계의 폐렴구균 백신 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSA 26.07.22Global Pneumococcal Vaccines Market size was valued at USD 8.66 Billion in 2024 and is poised to grow from USD 9.2 Billion in 2025 to USD 14.88 Billion by 2033, growing at a CAGR of 6.2% during the forecast period (2026-2033).
The global pneumococcal vaccines market is experiencing significant growth driven by the increasing demand for conjugate and polysaccharide immunizations to combat infections caused by Streptococcus pneumoniae, a pathogen responsible for severe illnesses such as pneumonia, meningitis, and sepsis. This market is particularly influenced by the global adoption of pediatric immunization programs and governmental efforts to fund vaccination initiatives in low- and middle-income countries, fostering demand for affordable vaccine options. Partnerships between manufacturers and regional companies are emerging as national health ministries allocate funds for routine immunization, leading to enhanced production capabilities and competitive pricing. Additionally, successful initiatives, such as the Gavi-supported rollout of vaccine programs, illustrate how strategic financing can stimulate market activity and expand opportunities for advanced vaccine development, distribution, and improved health outcomes worldwide.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pneumococcal Vaccines market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Pneumococcal Vaccines Market Segments Analysis
Global pneumococcal vaccines market is segmented by vaccine type, indication, age group, sector, distribution channel and region. Based on vaccine type, the market is segmented into pneumococcal conjugate vaccines (PCV) and pneumococcal polysaccharide vaccines (PPSV). Based on indication, the market is segmented into invasive pneumococcal disease, pneumonia, meningitis and otitis media. Based on age group, the market is segmented into pediatric, adult and geriatric. Based on sector, the market is segmented into public sector and private sector. Based on distribution channel, the market is segmented into government authorities, NGOs / international agencies and distribution partners. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Pneumococcal Vaccines Market
The global market for pneumococcal vaccines is experiencing substantial growth as governments around the world incorporate these vaccines into national immunization programs, targeting infants, the elderly, and high-risk groups. This policy shift is generating sustained demand across both public and private sectors, prompting manufacturers to enhance production capabilities and invest in robust distribution systems. By integrating pneumococcal vaccines into routine health services, health authorities facilitate broader population coverage, fostering increased confidence among healthcare professionals and caregivers. This reliable purchasing pattern not only stabilizes revenue streams but also propels continuous research and development in vaccine enhancements, further driving market expansion.
Restraints in the Global Pneumococcal Vaccines Market
The high costs associated with pneumococcal vaccines pose significant financial challenges for healthcare systems, especially in low- and middle-income regions. When procurement expenses surpass public health budgets, health authorities might opt for alternative measures or postpone the introduction of vaccines altogether. Such economic constraints diminish the number of doses that can be acquired, restricting market access in regions where disease prevalence is most severe. Consequently, this leads to inconsistent demand for manufacturers, hindering their ability to achieve economies of scale and potentially delaying the global dissemination of newer vaccine formulations across various continents in the foreseeable future.
Market Trends of the Global Pneumococcal Vaccines Market
The Global Pneumococcal Vaccines market is witnessing a significant trend towards the inclusion of adult immunization, as healthcare systems increasingly recognize the importance of protecting elderly and high-risk adult populations. This shift is spurred by a heightened awareness of the substantial burden posed by bacterial pneumonia, coupled with demographic changes reflecting an ageing population. As national immunization programs broaden their guidelines to encompass adult dosing, the demand for both conjugate and polysaccharide vaccine formulations is surging. Consequently, manufacturers are intensifying their focus on product development and strategic marketing, aiming to enhance distribution channels targeting senior care facilities and chronic-illness clinics across various sectors globally.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Pneumococcal Vaccines Market Size by Vaccine Type & CAGR (2026-2033)
- Market Overview
- Pneumococcal Conjugate Vaccines (PCV)
- PCV13 (Prevnar 13)
- PCV15 (Vaxneuvance)
- PCV20 (Prevnar 20)
- PCV21 (Capvaxive)
- Others
- Pneumococcal Polysaccharide Vaccines (PPSV)
- PPSV23 (Pneumovax 23)
Global Pneumococcal Vaccines Market Size by Indication & CAGR (2026-2033)
- Market Overview
- Invasive Pneumococcal Disease
- Pneumonia
- Meningitis
- Otitis Media
Global Pneumococcal Vaccines Market Size by Age Group & CAGR (2026-2033)
- Market Overview
- Pediatric
- Adult
- Geriatric
Global Pneumococcal Vaccines Market Size by Sector & CAGR (2026-2033)
- Market Overview
- Public Sector
- Private Sector
Global Pneumococcal Vaccines Market Size by Distribution Channel & CAGR (2026-2033)
- Market Overview
- Government Authorities
- NGOs / International Agencies
- Distribution Partners
Global Pneumococcal Vaccines Market Size & CAGR (2026-2033)
- North America (Vaccine Type, Indication, Age Group, Sector, Distribution Channel)
- US
- Canada
- Europe (Vaccine Type, Indication, Age Group, Sector, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Vaccine Type, Indication, Age Group, Sector, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Vaccine Type, Indication, Age Group, Sector, Distribution Channel)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Vaccine Type, Indication, Age Group, Sector, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co. Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline PLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Serum Institute of India Pvt. Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Vaxcyte Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- SK Bioscience Co. Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Walvax Biotechnology Co. Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bharat Biotech International Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Beijing Minhai Biological Technology Co. Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AIM Vaccine Co. Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Panacea Biotec Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- LG Chem Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takeda Pharmaceutical Company Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Biological E Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- KM Biologics Co. Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- CSL Behring
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca PLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Institut Pasteur de Dakar
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
